This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Panel Rejects Cephalon's Sparlon

Updated from 6:07 p.m. EST

Cephalon's (CEPH) drug for attention deficit hyperactivity disorder was rejected in a stunning decision by a panel of medical advisers to the Food and Drug Administration.

The advisory committee said Thursday the ADHD medication Sparlon needed more tests to assure safety against a rare and potentially fatal skin disease, even though the experts said the drug was effective. Additional tests could add at least a year to the regulatory process.

The advisory committee voted 12-to-1 against recommending Sparlon's approval, citing its concerns about Stevens-Johnson syndrome, a rare and vicious blistering of the skin that can be caused by certain drugs. The FDA isn't bound to follow its advisers' recommendations, but it usually does so.

"We are obviously disappointed with the recommendation of the advisory committee," said Dr. Paul Blake, Cephalon's executive vice president for worldwide medical and regulatory operations. "We will continue our discussions with the FDA to determine the next steps in the review of this drug application."

In September, an FDA staff member called attention to one case of the rare disease and two other cases of severe skin rash. He recommended that Sparlon be rejected. One month later, the agency granted Cephalon conditional approval for Sparlon, asking the company to provide more data on the skin problems and several other matters.

The advisory committee's decision is a major blow to Cephalon, which was seeking FDA approval for Sparlon to treat children ages 6 to 17. Cephalon's stock was halted Thursday while the panel deliberated, and the decision came after the markets had closed. A dramatic decline in its shares can be expected when trading resumes Friday.

The panel's ruling concluded two days of FDA hearings -- on Wednesday another advisory committee examined ADHD drugs in general -- and several roller-coaster weeks for Cephalon.

The Frazer, Pa., company's stock has bounced from the low $70s, to the low $80s, to the mid $60s and back to the low $70s as bits and pieces of clinical research and FDA analysis have become public.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
JNJ $112.11 -0.51%
LLY $75.14 -1.50%
NVS $74.97 -1.50%
PFE $33.80 0.30%
AAPL $95.14 -0.04%


Chart of I:DJI
DOW 17,706.25 -44.66 -0.25%
S&P 500 2,049.60 -13.77 -0.67%
NASDAQ 4,732.7250 -30.4990 -0.64%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs